Short answer
Astrana Health, Inc. (ASTH) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Form 8-K furnished under Item 2.02, limiting Section 18 Exchange Act liability.
Astrana Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Form 8-K furnished under Item 2.02, limiting Section 18 Exchange Act liability
- Content not incorporated into other Securities Act or Exchange Act filings unless expressly referenced
Item 7.01 · Regulation FD Disclosure
- Item 7.01 furnished under Regulation FD, limiting Section 18 liability exposure
- Disclosure excluded from automatic incorporation into other Securities Act or Exchange Act filings
Item EX-99.1 · Exhibit EX-99.2
- Q2 revenue $972.5M, up 49%; net income attributable to Astrana $19.7M, up 109%
- Adjusted EBITDA $68.9M, up 43%; adjusted diluted EPS $0.80, up 45%, with 7% adjusted EBITDA margin
- Six-month operating cash flow $100.8M and free cash flow $92.9M, supporting investment and deleveraging capacity
- 2026 adjusted EBITDA guidance raised to $255M-$280M; revenue guidance reaffirmed at $3.8B-$4.1B
- Texas agreement adds approximately 3,000 Medicare Advantage professional-risk lives; affiliated ACOs generated $120.4M gross shared savings
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Astrana Health, Inc. 8-K filings
Get the next ASTH 8-K as it lands
Follow ASTH for push alerts, or ask the research agent what this filing means.